Suppr超能文献

使用Amplatzer房间隔封堵器经导管封堵继发孔型房间隔缺损的长期预后

Long-term outcome of transcatheter secundum-type atrial septal defect closure using Amplatzer septal occluders.

作者信息

Masura Jozef, Gavora Pavol, Podnar Tomaz

机构信息

Children's Cardiac Center, University Children's Hospital, Bratislava, Slovakia.

出版信息

J Am Coll Cardiol. 2005 Feb 15;45(4):505-7. doi: 10.1016/j.jacc.2004.10.066.

Abstract

OBJECTIVES

The aim of this study was to assess long-term results of percutaneous closure of secundum-type atrial septal defect (ASD II) using Amplatzer septal occluders (ASO).

BACKGROUND

Only immediate-, short-, and intermediate-term results of ASO implantation are known so far.

METHODS

Between September 1995 and January 2000, 151 patients underwent a successful percutaneous closure of ASD II in our institution. All were included in the present study and were followed up until September 2004.

RESULTS

This group of patients was followed up from 56 to 108 months (median 78 months). The mean stretched defect diameter was 15.9 +/- 4.8 mm. There were no deaths or significant complications during the study. At three years of follow-up, all defects were completely closed and remained closed thereafter.

CONCLUSIONS

Since the first human implantations in September 1995, the Amplatzer septal occluder proved as a safe and effective device for percutaneous closure of ASD II.

摘要

目的

本研究旨在评估使用Amplatzer房间隔封堵器(ASO)经皮闭合继发孔型房间隔缺损(ASD II)的长期效果。

背景

迄今为止,仅知晓ASO植入的即刻、短期和中期效果。

方法

1995年9月至2000年1月期间,151例患者在我院成功接受了ASD II的经皮闭合术。所有患者均纳入本研究,并随访至2004年9月。

结果

该组患者的随访时间为56至108个月(中位时间78个月)。平均拉伸缺损直径为15.9±4.8毫米。研究期间无死亡或严重并发症发生。随访三年时,所有缺损均完全闭合,此后一直保持闭合状态。

结论

自1995年9月首次人体植入以来,Amplatzer房间隔封堵器被证明是一种安全有效的经皮闭合ASD II的装置。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验